|
Population
|
n
|
CFFCP1
|
CFFCP2
|
CFFCP3
|
CCP2
|
|---|
|
Rheumatoid arthritis
|
322
|
232 (72%)
|
251 (78%)
|
230 (71.4%)
|
238 (73.9%)
|
|
RF+
|
226
|
188 (83.2%)
|
199 (88.1%)
|
192 (85%)
|
199 (88.1%)
|
|
RF-a
|
95
|
43 (45.3%)
|
52 (54.7%)
|
38 (40%)
|
39 (41.1%)
|
|
Early
|
134
|
102 (76.1%)
|
104 (77.6%)
|
99 (73.9%)
|
99 (73.9%)
|
|
Anti-TNF-α treatment
|
78
|
56 (71.8%)
|
62 (79.5%)
|
61 (78.2%)
|
62 (79.5%)
|
|
Healthy blood donors
|
307
|
6 (2%)
|
6 (2%)
|
6 (2%)
|
6 (2%)
|
|
Systemic lupus erythematosus
|
119
|
11 (9.2%)
|
11 (9.2%)
|
9 (7.6%)
|
9 (7.6%)
|
|
Psoriatic arthritis
|
133
|
6 (4.5%)
|
13 (9.8%)
|
2 (1.5%)
|
4 (3%)
|
|
Hepatitis C virus infection
|
84
|
12 (14.3%)
|
2 (2.4%)
|
2 (2.4%)
|
1 (1.2%)
|
- aP < 0.0001 for all autoantibodies in comparison with RF+ rheumatoid arthritis. In one RA patient, RF status was not available. RF = rheumatoid factor; TNF = tumor necrosis factor.
